Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

Key Stats

• Today's Range: 118 to 119
• 50-Day Range: 118 to 135
• 52-Week Range: 82.50 to 136
• Volume: 4,000 shs
• Average Volume: 106,932 shs
• Market Capitalization: £100.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 160
• Consensus Rating: Buy

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 87 on January 1st, 2024. Since then, DXRX shares have increased by 36.8% and is now trading at GBX 119.
View the best growth stocks for 2024 here.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CUSIP: N/A
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 160
• High Stock Price Target: GBX 160
• Low Stock Price Target: GBX 160
• Potential Upside/Downside: +34.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 117.73
• P/E Growth: N/A
• Net Income: £-2,850,000.00
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.13%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 2.93
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £26.09 million
• Price / Sales: 3.85
• Cash Flow: GBX 38.14 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 46 per share
• Price / Book: 2.59

Miscellaneous

• Outstanding Shares: 84,470,000
• Free Float: N/A
• Market Cap: £100.52 million
• Optionable: Not Optionable
• Beta: 0.58